CSIMarket Company Name, Ticker, Industry, else..
 
Praxis Precision Medicines Inc   (NASDAQ: PRAX)
 
Price: $350.3000 $5.55 1.610%
Day's High: $351.7149963378906 Week Perf: -4.81 %
Day's Low: $ 333.46 30 Day Perf: 13.8 %
Volume (M): 341,761 52 Wk High: $ 392.70
Volume (M$): $ 0 52 Wk Avg: $262.51
Open: $343.00 52 Wk Low: $37.19



 Market Capitalization (Millions $) 10,118
 Shares Outstanding (Millions) 29
 Employees 168
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -327
 Cash Flow (TTM) (Millions $) 371
 Capital Exp. (TTM) (Millions $) 0

Business Description


Praxis Precision Medicines Inc is a biopharmaceutical company focused on discovering and developing targeted therapies for patients suffering from central nervous system disorders. The company leverages its expertise in neuroscience and genetic research to identify novel drug targets and develop precision medicines that address the underlying causes of these disorders. Praxis aims to provide patients with personalized treatments that can improve their quality of life.


   Company Address: 99 High Street Boston 2110 MA
   Company Phone Number: 300-8460   Stock Exchange / Ticker: NASDAQ PRAX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ACAD   -2.5%    
ALKS   -3.85%    
ARWR   -5%    
BMRN        0.25% 
SRPT        16% 
SUPN   -2%    
• View Complete Report
   



Announcement

Investor Vigilance Pomerantz Law Firm Launches Investigation into Praxis Precision Medicines, Inc.

Published Wed, Sep 10 2025 7:34 PM UTC

In recent developments within the biopharmaceutical sector, Pomerantz LLP has initiated an investigation aimed at safeguarding the interests of investors in Praxis Precision Medicines, Inc. (NASDAQ: PRAX). This article outlines the circumstances prompting this investigation and highlights the importance of investor vigilance in a turbulent financial landscape. Praxis P...
Shares

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Published Thu, Apr 3 2025 8:00 PM UTC

Praxis Precision Medicines: Strategic Stock Award to Enhance Team Capabilities Amid Promising Epilepsy BreakthroughsIn a recent development poised to influence both its human resources and financial narratives, Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a frontrunner in the biopharmaceutical field, has initiated significant stock-based incentives to bolster its talent...
Clinical Study

Transforming Epilepsy Treatment Praxis Precision Medicines Promising Breakthrough and Financial Journey

Published Tue, Sep 3 2024 11:30 AM UTC

In a significant stride towards innovative epilepsy management, Praxis Precision Medicines has unveiled promising topline results from its EMBOLD study, showcasing the disease-modifying potential of relutrigine for patients diagnosed with SCN2A and 8A developmental epilepsies. The study reported an impressive placebo-adjusted monthly motor seizure reduction of 46% during its...
Shares

Praxis Precision Medicines Grants Stock Options and Restricted Stock Units to New Employee in Line with Nasdaq Listing Rule 5635(c)(4)

Published Tue, Jun 4 2024 9:00 PM UTC

Praxis Precision Medicines Grants Stock Options and Restricted Stock Units to New Employee
BOSTON, June 4, 2024 - Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a pioneering clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, has announced the gran...
Shares

Praxis Precision Medicines Announces Inducement Grants and Pricing of Public Offering

Published Fri, May 3 2024 8:45 PM UTC



Praxis Precision Medicines, a clinical-stage biopharmaceutical company specializing in the development of therapies for central nervous system disorders, has made significant announcements regarding inducement grants and a public offering. The company aims to leverage its genetic insights to address the imbalances in neuronal excitation and inhibition. With a focus...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 7.18
PEG (TTM) -

Financial Strength Current
Quick Ratio 16.12
Working Capital Ratio 16.35
Leverage Ratio (MRQ) 0.03
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -13.82 $
Revenues (TTM) -
Cash Flow (TTM) 12.84 $
Cash 27.24 $
Book Value 48.82 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,943,649
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.